Rosenblatt analyst Blair Abernethy lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $200.00 (from $220.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE